Regardless of the stock price,_老虎社区_美港股上老虎

lemms
2021-08-31

Regardless of the stock price, I do hope that this is finally a cure for Alzheimer disease. It is a crippling disease.

AC Immune shares surged more than 70% in early trading

AC Immune shares surged more than 70% in early trading. AC Immune SA and its collaborating partner

AC Immune shares surged more than 70% in early trading

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":818599234,"tweetId":"818599234","gmtCreate":1630417869628,"gmtModify":1633678217200,"author":{"id":3562228884568927,"idStr":"3562228884568927","authorId":3562228884568927,"authorIdStr":"3562228884568927","name":"lemms","avatar":"https://static.tigerbbs.com/88c56965098d75b9e2f94e844a27d389","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":3,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Regardless of the stock price, I do hope that this is finally a cure for Alzheimer disease. It is a crippling disease.&nbsp;</p></body></html>","htmlText":"<html><head></head><body><p>Regardless of the stock price, I do hope that this is finally a cure for Alzheimer disease. It is a crippling disease.&nbsp;</p></body></html>","text":"Regardless of the stock price, I do hope that this is finally a cure for Alzheimer disease. It is a crippling disease.","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/818599234","repostId":1174676883,"repostType":4,"repost":{"id":"1174676883","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1630417268,"share":"https://www.laohu8.com/m/news/1174676883?lang=&edition=full","pubTime":"2021-08-31 21:41","market":"us","language":"en","title":"AC Immune shares surged more than 70% in early trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1174676883","media":"Tiger Newspress","summary":"AC Immune shares surged more than 70% in early trading.\n\n\nAC Immune SA and its collaborating partner","content":"<p>AC&nbsp;Immune&nbsp;shares&nbsp;surged&nbsp;more&nbsp;than&nbsp;70%&nbsp;in&nbsp;early&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/9e1ae2e20dee3043b692297f3834cf6d\" tg-width=\"878\" tg-height=\"616\" referrerpolicy=\"no-referrer\"></p>\n<ul>\n <li><b>AC Immune SA</b>&nbsp;and its collaborating partner&nbsp;<b>Genentech</b>, part of&nbsp;<b>Roche Holdings AG</b>, have&nbsp;announced topline data&nbsp;from Phase 2 study evaluating semorinemab in mild-to-moderate Alzheimer's disease (AD).</li>\n <li>Semorinemab met one of its co-primary endpoints, ADAS-Cog11 (cognitive scale). The second co-primary endpoint, ADCS-ADL (functional scale), was not met.</li>\n <li>Safety data showed that semorinemab was well tolerated with an acceptable safety profile and no unanticipated safety signals.</li>\n <li>Semorinemab demonstrated a statistically significant reduction in cognitive decline from baseline by 43.6% compared to placebo at week 49.</li>\n <li>There was no effect on the other co-primary endpoint of reducing the rate of functional decline. Genentech has reported that the open-label portion of the study will continue as planned.</li>\n <li>Further analyses are ongoing, and the company will submit topline data for presentation at the CTAD conference in November.</li>\n <li>Semorinemab is an investigational monoclonal anti-tau antibody that targets the N-terminal portion of the tau protein and is designed to bind to tau and slow its spread between neurons.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AC Immune shares surged more than 70% in early trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAC Immune shares surged more than 70% in early trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-31 21:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>AC&nbsp;Immune&nbsp;shares&nbsp;surged&nbsp;more&nbsp;than&nbsp;70%&nbsp;in&nbsp;early&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/9e1ae2e20dee3043b692297f3834cf6d\" tg-width=\"878\" tg-height=\"616\" referrerpolicy=\"no-referrer\"></p>\n<ul>\n <li><b>AC Immune SA</b>&nbsp;and its collaborating partner&nbsp;<b>Genentech</b>, part of&nbsp;<b>Roche Holdings AG</b>, have&nbsp;announced topline data&nbsp;from Phase 2 study evaluating semorinemab in mild-to-moderate Alzheimer's disease (AD).</li>\n <li>Semorinemab met one of its co-primary endpoints, ADAS-Cog11 (cognitive scale). The second co-primary endpoint, ADCS-ADL (functional scale), was not met.</li>\n <li>Safety data showed that semorinemab was well tolerated with an acceptable safety profile and no unanticipated safety signals.</li>\n <li>Semorinemab demonstrated a statistically significant reduction in cognitive decline from baseline by 43.6% compared to placebo at week 49.</li>\n <li>There was no effect on the other co-primary endpoint of reducing the rate of functional decline. Genentech has reported that the open-label portion of the study will continue as planned.</li>\n <li>Further analyses are ongoing, and the company will submit topline data for presentation at the CTAD conference in November.</li>\n <li>Semorinemab is an investigational monoclonal anti-tau antibody that targets the N-terminal portion of the tau protein and is designed to bind to tau and slow its spread between neurons.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ACIU":"AC Immune SA"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174676883","content_text":"AC Immune shares surged more than 70% in early trading.\n\n\nAC Immune SA and its collaborating partner Genentech, part of Roche Holdings AG, have announced topline data from Phase 2 study evaluating semorinemab in mild-to-moderate Alzheimer's disease (AD).\nSemorinemab met one of its co-primary endpoints, ADAS-Cog11 (cognitive scale). The second co-primary endpoint, ADCS-ADL (functional scale), was not met.\nSafety data showed that semorinemab was well tolerated with an acceptable safety profile and no unanticipated safety signals.\nSemorinemab demonstrated a statistically significant reduction in cognitive decline from baseline by 43.6% compared to placebo at week 49.\nThere was no effect on the other co-primary endpoint of reducing the rate of functional decline. Genentech has reported that the open-label portion of the study will continue as planned.\nFurther analyses are ongoing, and the company will submit topline data for presentation at the CTAD conference in November.\nSemorinemab is an investigational monoclonal anti-tau antibody that targets the N-terminal portion of the tau protein and is designed to bind to tau and slow its spread between neurons.","news_type":1},"isVote":1,"tweetType":1,"viewCount":275,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":97,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}

AC Immune shares surged more than 70% in early trading

评论（1）

热议股票